Patient Inclusion Criteria

- Have a diagnosis of congenital Alpha1-antitrypsin deficiency (AATD) with an allelic combination of ZZ, SZ, Z(null), (null)(null), S(null), or "at-risk" alleles (subjects with "at-risk" alleles must be individually evaluated for eligibility by the Medical Monitor). - Have a documented pre-Alpha1-Proteinase Inhibitor (PI) augmentation therapy serum alpha-1 antitrypsin (AAT) level <11 micrometer (μM) (80 milligrams per decilitre (mg/dL) if measured by radial immunodiffusion or 50 mg/dL if measured by nephelometry). - Currently receiving Alpha1-PI augmentation therapy or has received Alpha1-PI augmentation therapy within the past. If the subject is currently receiving Alpha1-PI augmentation therapy of any kind, he/she must be willing to discontinue that treatment at the Week 1 (Baseline) Visit and remain off any kind of Alpha1-PI treatment, other than the IPs for this study, while participating in the study. Note: Subjects must not be naïve to Alpha1-PI augmentation therapy for study participation. - At the Screening Visit, have a post-bronchodilator forced expiratory volume (FEV1) ≥30% and <80% of predicted and FEV1/forced vital capacity (FVC) <70% (Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage II or III).

Patient Exclusion Criteria

1. Not receiving invasive mechanical ventilation or non invasive ventilation2. More than 96 hours from the onset of ARDS3. Age < 18 years4. Known to be pregnant or breastfeeding5. Participation in a clinical trial of interferon therapies, immune plasma therapies or immunoglobulin within 30 days6. Major trauma in the prior 5 days7. Presence of any active malignancy (other than non-melanoma skin cancer) that required treatment within the last year8. WHO Class III or IV pulmonary hypertension9. Pulmonary embolism within past 3 months10. Currently receiving extracorporeal life support (ECLS)11. Currently receiving renal replacement therapy12. Severe chronic liver disease with Child-Pugh score > 1213. DNAR (Do Not Attempt Resuscitation) order in place14. Treatment withdrawal imminent within 24 hours15. Prisoners16. Non-English speaking patients or those who do not adequately understand verbal or written information unless an interpreter is available.17. Enrolled in a concomitant clinical trial of interferon therapies, immune plasma therapies or immunoglobulin.18. IgA deficiency